- Home
- RGA vs MRNA Comparison
RGA vs MRNA Comparison
Compare RGA & MRNA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- RGA
- MRNA
- Stock Information
- Founded
- RGA 1973
- MRNA 2010
- Country
- RGA United States
- MRNA United States
- Employees
- RGA N/A
- MRNA N/A
- Industry
- RGA Life Insurance
- MRNA Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- RGA Finance
- MRNA Health Care
- Exchange
- RGA Nasdaq
- MRNA Nasdaq
- Market Cap
- RGA 12.1B
- MRNA 13.4B
- IPO Year
- RGA 1993
- MRNA 2018
- Fundamental
- Price
- RGA $188.25
- MRNA $28.02
- Analyst Decision
- RGA Buy
- MRNA Hold
- Analyst Count
- RGA 12
- MRNA 20
- Target Price
- RGA $242.27
- MRNA $46.24
- AVG Volume (30 Days)
- RGA 537.0K
- MRNA 8.6M
- Earning Date
- RGA 07-31-2025
- MRNA 08-01-2025
- Dividend Yield
- RGA 1.98%
- MRNA N/A
- EPS Growth
- RGA N/A
- MRNA N/A
- EPS
- RGA 11.51
- MRNA N/A
- Revenue
- RGA $21,751,000,000.00
- MRNA $3,078,000,000.00
- Revenue This Year
- RGA $7.04
- MRNA N/A
- Revenue Next Year
- RGA $10.28
- MRNA $10.04
- P/E Ratio
- RGA $16.35
- MRNA N/A
- Revenue Growth
- RGA 1.76
- MRNA N/A
- 52 Week Low
- RGA $159.25
- MRNA $23.15
- 52 Week High
- RGA $233.81
- MRNA $91.99
- Technical
- Relative Strength Index (RSI)
- RGA 47.62
- MRNA 46.33
- Support Level
- RGA $185.81
- MRNA $25.30
- Resistance Level
- RGA $189.97
- MRNA $27.08
- Average True Range (ATR)
- RGA 4.92
- MRNA 1.33
- MACD
- RGA 0.62
- MRNA -0.31
- Stochastic Oscillator
- RGA 73.85
- MRNA 32.38
About RGA Reinsurance Group of America Incorporated
Reinsurance Group of America Inc is an insurance holding company with operations in the United States, Latin America, Canada, Europe, Africa, Asia, and Australia. The core products and services include life reinsurance, living benefits reinsurance, group reinsurance, health reinsurance, financial solutions, facultative underwriting, and product development. The company's operations are divided into traditional and financial solution businesses.
About MRNA Moderna Inc.
Moderna is a commercial-stage biotech that was founded in 2010 and had its initial public offering in December 2018. The firm's mRNA technology was rapidly validated with its covid vaccine, which was authorized in the United States in December 2020. Moderna had 40 mRNA development candidates in clinical development as of September 2024. Programs span a wide range of therapeutic areas, including infectious disease, oncology, cardiovascular disease, and rare genetic diseases.